1,318 zoekresultaten voor “anti-cancer drug steen” in de Publieke website
-
Development of novel anti-cancer strategies utilizing the zebrafish xenograft model
In this thesis, we will utilize embryonic zebrafish tumour models to understand the interaction between engrafted human cancer cells and macrophages from the host, test drug administration modalities and anti-cancer efficacies of newly-developed PDT and PACT compounds, and test a light-triggered liposomal…
-
Upconverting nanovesicles for the activation of ruthenium anti-cancer prodrugs with red light
Promotor: E. Bouwman, Co-promotor: S. Bonnet
-
Dick van der SteenISSC
d.c.van.der.steen@issc.leidenuniv.nl | +31 71 527 2727
-
Tamara van den SteenFaculteit der Wiskunde en Natuurwetenschappen
t.m.van.den.steen@lacdr.leidenuniv.nl | 071 5272727
-
Joesjka van der SteenUniversitair Facilitair Bedrijf
j.van.der.steen@ufb.leidenuniv.nl | 071 5272727
-
Pulling the strings on anti-cancer immunity
Promotores: J. Jonkers, K.E. de Visser
-
Bart van der SteenUniversitaire Bibliotheken Leiden
b.s.van.der.steen@library.leidenuniv.nl | 071 5272727
-
Jeltje van der SteenASSC
j.van.der.steen@assc.leidenuniv.nl | 071 5273179
-
Jasper van der SteenFaculteit der Geesteswetenschappen
j.a.van.der.steen@hum.leidenuniv.nl | 071 5271492
-
Tommy van SteenFaculteit Governance and Global Affairs
t.van.steen@fgga.leidenuniv.nl | 070 8009500
-
Photo-activated drug delivery systems
O-Nitrobenzyl groepen worden veel gebruikt als moleculaire beschermgroepen die je met licht kunt verwijderen.
-
Mechanistic modelling of drug target binding kinetics as determinant of the time course of drug action in vivo
Drug-target binding kinetics determine the time course of the central event in pharmacotherapy: Drug-target interaction.
-
Modern Drug Discovery
How are new drugs developed? This question is central to the Minor Modern Drug Discovery (MDD), which covers the entire trajectory from disease to drug molecule and vice versa. The various research groups involved offer a complementary and interdisciplinary perspective by connecting the diverse subjects…
-
Dynamics of TNFalpha signaling and drug-related toxicity
In previous studies at our laboratory it was demonstrated that drug exposure of HepG2 cells can lead to an altered TNFα-induced NF-κB oscillatory phenotype, concurrent with a synergistically increased sensitivity for TNFα-induced apoptosis.
-
Reverse engineering of drug induced QT(c) interval prolongation: Towards a systems pharmacology approach
Promotor: M. Danhof Co-promotor: O.E. Della Pasqua
-
A pharmacognostic study of Vernonia guineensis Benth. (Asteraceae): bioactivity, safety, and phytochemical analysis
Promotor: Prof.dr. R. Verpoorte, Co-Promotor: Dr. Young Hae Choi
-
Drug Discovery & Safety
In het onderzoeksprogramma Drug Discovery & Safety zijn we geïnteresseerd in de werkzaamheid en veiligheid van nieuwe medicijnen en nieuwe manieren om deze aspecten te bepalen. Daarvoor combineren we geavanceerde imaging en high-throughput screening technieken met computationele aanpakken zoals chem-…
-
Disease, Signaling and Drug Targets
The Minor Computational Approaches to Disease, Signaling and Drug Targets (CADSDT) is focused on fundamental scientific research required for discovery of new drug targets and development of new drugs.
-
Robotic reconstitution of cytostatic drugs and monoclonal antibodies: transforming aseptic drug compounding in hospital pharmacies
Hospital pharmacies face significant challenges: the demand for sterile drug reconstitutions is increasing, while specialized personnel remain scarce. Automation offers a potential solution, but its practical implementation in hospitals is still unclear.
-
Prediction of spatial-temporal brain drug distribution with a novel mathematical model
A novel mathematical model describes spatial-temporal drug distribution within one or more brain units, which are cubic representations of a piece of brain tissue with brain capillaries at the edges.
-
Advanced in vitro models for studying drug induced toxicity
Promotor: B.van de Water, Co-promotor: L.S.Price
-
Ginsenosides as selective glucocorticoid drugs: agonists, antagonists, and prodrugs
Glucocorticoids are potent anti-inflammatory drugs widely used clinically to treat various inflammatory and immune conditions. However, two main clinical problems limit their use. GCs trigger severe side effects and they induce acquired glucocorticoid resistance, especially during chronic systemic treatment…
-
Ruthenium-peptide conjugates for targeted phototherapy
As leading cause of death worldwide, cancer is responsible for nearly 10 million deaths in 2020 according to World Health Organization (WHO). Cisplatin and its derivatives are commonly used chemotherapy agents for current cancer treatment in the clinics.
-
Activity-based protein profiling in drug discovery
In the last decades, activity-based protein profiling (ABPP) has emerged as a powerful chemical tool that may aid the ever-challenging drug discovery process.
-
To explore the drug space smarter: Artificial intelligence in drug design for G protein-coupled receptors
Over several decades, a variety of computational methods for drug discovery have been proposed and applied in practice. With the accumulation of data and the development of machine learning methods, computational drug design methods have gradually shifted to a new paradigm, i.e. deep learning methods…
-
Pharmacogenomics in drug development: implementation and application of PKPD model based approaches
Promotor: Prof.dr. M. Danhof, Co-Promotor: J. de Jongh
-
Towards improved drug action : target binding kinetics and functional efficacy at the mGlu2 receptor
During the course of drug discovery translational steps are made.
-
The impact of non-genetic factors on drug metabolism: towards better phenotype predictions
This thesis investigates how non-genetic factors, such as inflammation and concomitant medication, impact hepatic drug metabolism and subsequent drug metabolizing phenotype predictions.
-
Microengineered Human Blood Vessels For Next Generation Drug Discovery
Heart failure is a major health care problem with high mortality.
-
Proteins in harmony: Tuning selectivity in early drug discovery
This thesis describes the importance of being able to control the selectivity of potential drug candidates.
-
mRNA and drug delivery with lipid-based nanoparticles
This thesis focuses on the application of lipid-based nanomedicine in drug delivery, including small molecular antitumor drugs and biomacromolecules including mRNA, and evaluates their biological performance.
-
vesicles: An efficient membrane biophysical tool and its application in drug delivery studies
Promotor: A. Kros
-
Anthracycline biosynthesis in Streptomyces: engineering, resistance and antimicrobial activity
Actinobacteria are well known for the production of bioactive natural products, many of which have applications in the fields of human, animal and plant health. Subject of this thesis are the anthracyclines, glycosylated aromatic polyketides with potent anticancer activity.
-
Waarom zijn drugs verslavend?
Een pilletje op een festival, een biertje in de kroeg, of een sigaret bij de koffie. We wéten dat het slecht voor ons is, maar doen het toch. Hoe komt dat?
-
Systems pharmacokinetic models to the prediction of local CNS drug concentrations in human
Clinical development of drugs for central nervous system (CNS) disorders has been particularly challenging and still suffers from high attrition rates.
-
Time is of the essence: investigating kinetic interactions between drug, endogenous neuropeptides and receptor
Promotor: A.P. IJzerman Co-promotor: L.H. Heitman
-
A chemical biology approach for targeting of ligand-drug conjugates
Promotores: H.S. Overkleeft, G.A. van der Marel, Co-Promotor: R.G. Boot
-
In vivo modelling of Ewing sarcoma in zebrafish
Promotores: Prof.dr. P.C.W. Hogendoorn & Prof.dr. H.P. Spaink Co-promotor: Dr. B.E. Snaar-Jagalska
-
How to scale clearance from adults to children for drugs undergoing hepatic metabolism?
The aim of this thesis is to expedite and ensure the systematic accuracy of clearance scaling from adults to paediatric patients, with a special focus on drugs undergoing hepatic metabolism.
-
namic Relationships of Central Nervous Systems Active Dopaminergic Drugs
Discovery and development of Central Nervous System (CNS) drugs is hampered by high attrition rates.
-
Drug-target residence time: a case for the adenosine A1 and A2A receptors
Promotor: A.P.IJzerman, Co-Promotor: L.H. Heitman
-
Transforming data into knowledge for intelligent decision-making in early drug discovery
Promotor: A.P.IJzerman Co-promotor: A. Bender
-
Systems microscopy to unravel cellular stress response signalling in drug induced liver injury
Promotor: B. van de Water
-
quantification of growth hormone secretion : application of model-informed drug development in acromegaly
Growth hormone profiles are pulsatile and highly variable between individuals, limiting the implementation of mathemathical models to quantify an individual's secretion.
-
The impact of obesity on the pharmacokinetics of drugs in adolescents and adults
Promotores: C.A.J. Knibbe; J.N. van den Anker, Co-promotores: H.P.A. van Dongen; B. van Ramshorst
-
Antibiotic Conjugates and Natural Products as Next-Generation Strategies Against Antimicrobial Resistance
This thesis tackles the urgent challenge of antimicrobial resistance (AMR) through the design of novel antibacterial agents.
-
Pharmacogenomics in Drug Development: Implementation and Application of PKPD Model Based Approaches
Model based approaches, integrating physiological parameters or linking exposure with response, are powerful tools to quantify and evaluate the impact of genetic differences that are reflected as variability of drug exposure and/or clinical response(s). This thesis “Pharmacogenomics in Drug Development: …
-
Personalised pharmacotherapy in paediatric epilepsy : the path to rational drug and dose selection
The path to rational drug and dose selection
-
Getting personal: Advancing personalized oncology through computational analysis of membrane proteins
Cancer is considered the silent pandemic of the 21st century and the second leading cause of death worldwide.
-
using fluorescent cell models for mechanistic evaluation of adverse drug reactions
Promotie